All Work

Chris Lange

Is the Worst Over for Apple?

Despite the ongoing trade war between the United States and China, one analyst has a surprisingly bullish take on Apple.

Chris Lange · 7 years ago

How Tonix Pharma Is Kicking Cocaine

Tonix Pharmaceuticals shares jumped on Thursday after the firm announced that it has in-licensed a Phase 2 asset, TNX-1300 for the treatment of cocaine intoxication.

Chris Lange · 7 years ago

How Eli Lilly Is Making Insulin More Affordable

Eli Lilly has announced that its Insulin Lispro Injection is now available for order in pharmacies for people who use its rapid-acting insulin and need a lower-cost option.

Chris Lange · 7 years ago

How Lowe’s Earnings Measure Up Against Home Depot

Lowe’s reported its most recent quarterly results early on Wednesday, and unfortunately they don’t stack up well against rival Home Depot, which reported earlier this week.

Chris Lange · 7 years ago

Why Ocular Therapeutix Fell Short in Its Glaucoma Study

Ocular Therapeutix shares took a beating on Tuesday after the firm announced late-stage results for patients with primary open-angle glaucoma or ocular hypertension. These results come from the Phase 3 clinical trial of OTX-TP,…

Chris Lange · 7 years ago

What to Expect When Target Reports Wednesday

Target is scheduled to release its fiscal first-quarter financial results before the markets open on Wednesday and analysts are looking for solid year-over-year growth.

Chris Lange · 7 years ago

Do Kohl’s Q1 Results Signal Trouble?

Kohl’s reported mixed first-quarter financial results before the markets opened on Tuesday, and shares tumbled afterward.

Chris Lange · 7 years ago

Why BioCryst’s HAE Treatment Failed to Impress

BioCryst Pharmaceuticals shares were absolutely crushed in Tuesday’s session after the company announced late-stage results for its study in hereditary angioedema patients.

Chris Lange · 7 years ago